Golden Biotechnology Corporation (TPEX:4132)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
14.20
-0.60 (-4.05%)
Mar 3, 2026, 1:59 PM CST
-7.79%
Market Cap 2.40B
Revenue (ttm) 44.58M
Net Income (ttm) -314.93M
Shares Out 162.23M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 589,020
Average Volume 881,963
Open 14.80
Previous Close 14.80
Day's Range 14.05 - 14.80
52-Week Range 9.98 - 36.30
Beta 0.46
RSI 33.35
Earnings Date Apr 27, 2026

About Golden Biotechnology

Golden Biotechnology Corporation engages in research and development of new drug in Taiwan. The company offers Antroquinonol for the treatment of pancreatic cancer, acute myeloid leukemia, blood diseases, non-small cell lung cancer, COVID-19, and other diseases. It is also involved in development and sale of health foods and supplements, as well as provides products for oncology, infectious, and neurodegenerative diseases. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan. [Read more]

Sector Healthcare
Founded 2002
Employees 122
Stock Exchange Taipei Exchange
Ticker Symbol 4132
Full Company Profile

Financial Performance

In 2024, Golden Biotechnology's revenue was 40.92 million, a decrease of -35.49% compared to the previous year's 63.43 million. Losses were -360.70 million, -0.26% less than in 2023.

Financial Statements

News

There is no news available yet.